Federal Agencies scrutinize lung surgery. by unknown
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The smart ones are goinggreen, the dumb ones are not,
andthe foolish ones arepretendiQg.
David Krents, on corporate environmental policy,
quoted in GlobeandMail(Toronto)
13 October 1990 Forum
California Bans Pesticides
After requesting that studies be submitted
on the toxicity of200 chemicals commonly
used in pesticides, officials at the California
Department ofPesticide Regulation (DPR)
have decided that not enough is known
about three of these chemicals to allow
their continued use in the state. By the
beginning of October, the manufacturers
of23 pesticide products that contain these
chemicals will have been notified by the
department that their products are no
longer registered for manufacture or sale in
California, according to Veda Federighi,
communications director for the DPR.
The suspension will involve products
containing the fungicide chloreneb, the
wood preservative creosote, and aromatic
petroleum distil-
lates, which are
commonly used in
insecticides. The
DPR said it is j
suspending prod-
ucts that contain
these compounds
because manufac-
turers failed to
comply with a
March 30 deadline
for submitting tox-
icity studies show-
ing that the com-
pounds are safe.
After the suspen-
sion takes effect, reg-
istrants will be prohib-
ited from making or sel-
ing the products, but retail
dealers will have two years to sell
their remaining stocks. In addition, the
suspension will be lifted and the registra-
tion reinstated if manufacturers submit all
required-studies after the suspension takes
effect or ifthe manufacturer can show that
use of the chemical results in insignificant
human exposure.
According to Jacqueline Fernette, coor-
dinator of corporate communication for
Reilly Industries, Inc., one ofthe companies
that sold creosote products in California,
her company simply decided that complet-
ing the requested toxicity studies was not
cost efficient. "[The suspension] certainly
effects Reilly, but in a small way," Fernette
said. "We tried, along with other suppliers,
to get [California] to accept testing we were
currently doing for the EPA, but apparently
they didn't feel it was sufficient." Fernette
said that creosote is not a particularly haz-
ardous chemical, but that "it is a chemical
thatmust bedealtwith appropriately."
The process of collecting data on the
200 chemicals came about as a result ofthe
1985 Birth Defects Prevention Act (SB
950), which mandated that the state collect
data on all pesticide active ingredients so
that potential chronic health effects could
be evaluated. For each pesticide ingredient,
10 studies are usually required, including
animal studies on chronic toxicity, onco-
genicity, teratogenicity, reproductive toxic-
ity, genotoxicity, neurotoxicity, and muta-
genicity. A 1991 amendment to the law
required that companies using any of the
200 chemicals in their products supply the
department with any missing studies or
face suspension oftheir registrations. "It is
similar to the datacollection going on
at the federal level, but on a
more expedited schedule,"
said James W. Wells, direc-
tor of the DPR, in a press
release. "No state has ever
attempted to master the
logistics of such an
undertaking or the sci-
ence required to sup-
port it."
Though almost
all data have
been submitted,
Federighi says,
"The real work
ofSB 950 begins
now."According
to Federighi, sci-
entists at the
DPRmust nowreviewall submitted studies
and make sure that the data are adequate
according to EPAguidelines. Next, the data
will be scanned for any significant adverse
effects brought to light by the studies.
"Based on our findings," Federighi said,
"we will ... prioritize the chemicals for risk
assessment. Ifwe get something that's a real
red flag, we will act on it immediately."
After it is finished dealingwith all 200 "pri-
ority chemicals," the department must then
face the larger task of going through the
same process for all other pesticide active
ingredients.
Chloroneb, creosote, and aromatic
petroleum distillates are not the only three
pesticide ingredients out of the original
200 that will no longer be registered with
the DPR for use in California. As a result
ofthe SB 950 legislation, registrations were
not renewed or were withdrawn by the
manufacturers of products containing 44
other active ingredients. Some ofthese reg-
istrants withdrew their products rather
than pay for costly toxicological testing,
although, according to the DPR, other fac-
tors were often involved. Products contain-
ing seven other active ingredients had their
registrations revoked for failure to comply
with earlier data submission requirements.
All data requirements have been met for
144 compounds, including diphacinone
and formaldehyde, which were in danger of
suspension earlier this year. Because of
1996 legislation, studies on two chemicals,
methyl bromide and pentachlorophenol,
are not due until December 1997.
Federal Agencies Scrutinize
Lung Surgery
When St. Louis surgeon Joel Cooper began
experimenting with a new form of lung
surgery in 1993, emphysema patients
rejoiced. For many, his lung volume reduc-
tion surgery (LVRS) offered their onlyhope
for resuming a normal life. Traditional
treatment, with drugs and rehabilitation,
provides only temporary relief and, while
lung transplant offers a cure, its high risk
severelylimits its use.
As news ofCooper's promising surgery
spread, surgeons nationwide adopted his
technique. More than 3,000 emphysema
patients had received LVRS by December
1995, when officials from the Health Care
Financing Administration made the sur-
prising announcement that Medicare
would no longer cover the cistly proce-
dure. "There [were] not enough data for us
to assess the risks and benefits," explained
Steven Sheingold, director of HCFA's
technology andspecial analysis staff.
HCFA's decision prompted a flurry of
protest from many of the 2 million
Americans suffering from emphysema. Last
April, HCFA officials announced they
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would resume payment in 1997, but only
for a limited number ofpatients participat-
ing in a seven-year study to be conducted
by the National Institutes ofHealth.
HCFA's announcement stirred up
strong sentiments among medical profes-
sionals accustomed to hashing out the pros
and cons of new procedures among them-
selves. Many agree on the need for further
research. Others, however, dismiss the
study as a political move to cut costs. Lung
reduction surgery costs between $35,000
and $70,000.
Although often considered new, LVRS
dates back to the late 1950s, when
University of Maryland surgeon Otto
Brantigan performed the surgery on 33
patients. Brantigan theorized that emphy-
sema patients would breathe more easily
with smaller lungs. An emphysematous
lung expands as the disease breaks down
the walls in the spongy organ's air sacs.
Pressure from the distended lungs prevents
the diaphragm from pushing air out effec-
tively. By reducing the lungs' size,
Brantigan believed he could improve the
mechanics of the breathing muscles.
Unfortunately, he had no means of mea-
suring his patients' improvement. His pro-
cedure was largely forgotten until its recent
revival, led by Cooper at Barnes Hospital
in St. Louis.
Cooper typically splits his patients'
sternums and uses a scalpel to remove
20-30% ofeach lung. His first 20 patients
demonstrated a remarkable 82% increase
in their forced expiratory volume, the
amount ofair they can blow out. Seventy-
one percent were able to give up supple-
mental oxygen. Other surgeons report sub-
stantial improvements in at least two-
thirds of their LVRS patients. "Our
patients feel dramatically better and
breathe better," said John Chen, assistant
chief of cardiothoracic surgery at the
University of California-Irvine Medical
Center.
But what about the minority ofpatients
who fail to improve, and the 5-10% who
die? Will patients who have had the surgery
live any longer than those receiving tradi-
tional treatment with drugs and rehabilita-
tion? These are among the questions NIH
officials expect their study to answer. The
NIH's National Heart, Lung and Blood
Institute will manage the study, which is
slated to begin in 1997. Approximately 15
medical centers will be chosen to conduct
clinical trials. Approximately 3,000 patients
will participate. All will receive intensive
pulmonary rehabilitation and drug therapy.
Half, chosen at random, then will undergo
LVRS. Researchers will compare the
progress ofthe two groups.
Those who support the study point out
the need for more data. "We should know
up front who improves and who does not,"
saidJonathon Truwit, interim division chief
of pulmonary and critical care medicine at
the University ofVirginia in Charlottesville.
"Ifwe're setting these patients' clocks back,
let's find outhowfarback."
Pulmonologist and ethicist MarkTonelli
of the University ofWashington in Seattle
pointed out the government's success in reg-
ulating the pharmaceutical industry. "Ifthis
were a new drug, instead of a new type of
surgery, the Food and Drug Administration
would require extensive testing," he said. "I
think thestudy is agoodmodel."
Critics object to the random selection
that will deny surgery to half the candi-
dates. They say drugs and rehabilitation
have never produced the dramatic improve-
ments seen in some LVRS patients. "We
see this as a government ploy to hold back
expenses," said Rodney Landreneau, head
of thoracic surgery at Allegheny General
Hospital in Pittsburgh.
HCFA's Sheingold countered, "We do
not base our decisions on cost. We base our
decisions on effectiveness. However, we're
all forced to assure the highest quality of
care while containing costs." Sheingold
added that the LVRS study may be just a
hint offuture government oversight ofsur-
gical procedures. "HCFA and the NIH are
looking into studying other areas, including
kidney/pancreas transplants," he said. "This
is a long overdue marriage of the payment
agency and the best scientific agency to pro-
vide data aboutwhatworks in health care."
Promising Lung Cancer Vaccine
An antibody developed by researchers at
Memorial Sloan-Kettering Cancer Center
(MSKCC) appears to prolong the lives of
patients with small cell lung cancer.
Patients who received injections containing
the antibody BEC2 and Mycobacterium
bovis, a strain of bacteria that stimulates
the immune system, were found to live
longer than patients who received only the
standard treatment for small cell lung can-
cer, which is chemotherapy with or with-
out radiation. Small cell lung cancer is usu-
ally fatal, with a 15-20% long-term sur-
vival rate for patients in whom the cancer
is contained to the chest, and only a 0-5%
long-term survival rate for those in whom
the cancer has spread beyond the chest.
The current median survival period, for
patients diagnosed with small cell lung
cancer, is 7-14 months.
To create BEC2, the researchers emu-
lated the structure of GD3 ganglioside, a
nonprotein molecule found in certain can-
A shot in the lungs. A new antibody may help
patients with small cell lung cancer live longer.
cer cells, such as small cell lung and
melanoma. GD3 is not recognized by the
body as a foreign molecule and therefore
does not usually trigger an immune
response, says Stefan Grant, an attending
physician at MSKCC and co-principal
investigator of the project to develop the
antibody. The researchers found that
BEC2 is recognized as foreign and, because
their structures are similar, stimulates the
production of antibodies against both
BEC2 and GD3. The antibodies signal the
immune system to destroy the cells con-
taining GD3 and BEC2, thus eliminating
the cancer.
MSKCC researchers conducted a clini-
cal trial on eight patients with small cell
lung cancer who had received chemothera-
py. The researchers administered the vac-
cine to the participants five times during a
period of 10 weeks. Six ofthe participants
completed the immunizations and were
evaluated, and four ofthese were found to
be free of the cancer and healthy three
years after their diagnoses.
The control group for this study con-
sisted of34 patients who had received simi-
lar chemotherapy at MSKCC. The median
survival for this group was 16.2 months,
whereas the median survival for the group
treated with BEC2 was more than 36
months. The study was presented at the
American Society of Clinical Oncology
annual meeting in May in Philadelphia.
The only side effect seen thus far is a
local reaction at the site of the injections,
which is manifested by inflammation and
leaves ascar, said Grant. MSKCC researchers
are now planning a larger study to test the
vaccine. "We are planning a large random-
ized phase-3 trial, which we anticipate [to be
conducted] towards the middle ofnextyear,"
Grant said. The study will involve more
patients and alarger control group.
Although the vaccine has not yet been
thoroughly tested, MSKCC researchers are
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